M.D. Anderson to Hold Conference in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

HOUSTON--The University of Texas M.D. Anderson Cancer Center will hold its second medical oncology conference in Spanish on May 22-24, 1996. The educational conference will bring together physicians from Spain and Latin American with the M.D. Anderson faculty, said Richard Pazdur, MD, associate professor of medicine and co-director of the conference along with Alejandro Preti, MD, assistant professor of medicine.

HOUSTON--The University of Texas M.D. Anderson Cancer Center willhold its second medical oncology conference in Spanish on May22-24, 1996. The educational conference will bring together physiciansfrom Spain and Latin American with the M.D. Anderson faculty,said Richard Pazdur, MD, associate professor of medicine and co-directorof the conference along with Alejandro Preti, MD, assistant professorof medicine.

"I think M.D. Anderson is unique in that it has such a diversegroup of Spanish-speaking faculty, both native speakers and thosewho learned the language along the way," Dr. Pazdur saidin an interview. Most of the speakers are M.D. Anderson faculty.In addition, physicians from Spain have been invited to discusstheir research work at a symposium to be held in conjunction withthe conference.

ASCO Findings Will Be Reviewed

The meeting will also provide an opportunity for a discussionof studies presented at the 1996 American Society of ClinicalOncology (ASCO) meeting, to put new findings into the contextof existing therapies, Dr. Pazdur said. He expects between 50and 100 physicians to attend the conference.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content